Uremic bleeding syndrome: Difference between revisions
No edit summary |
|||
| Line 24: | Line 24: | ||
**Recombinant EPO 50 - 150 u/kg IV 3x/wk | **Recombinant EPO 50 - 150 u/kg IV 3x/wk | ||
**Conjugated estrogens at 0.6 mg/kg IV over 30 min QD for 5 days - time to effect ~ 6 hrs, max effect at 1 wk, duration of action 2 wks | **Conjugated estrogens at 0.6 mg/kg IV over 30 min QD for 5 days - time to effect ~ 6 hrs, max effect at 1 wk, duration of action 2 wks | ||
==See Also== | |||
*[[Coagulopathy]] | |||
==References== | ==References== | ||
Revision as of 11:40, 8 November 2015
Background
- Bleeding diathesis
- Increased risk for of bleeding (GI, ICH, liver hematoma) due to impaired platlet function
Clinical Features
- Wide range of presentations
- Ecchymosis, purpura, epistaxis, fistula bleeding, venipuncture bleeding
- GI bleeding
- Intracranial bleeding
Differential Diagnosis
Coagulopathy
Platelet Related
- Too few
- Nonfunctional
Factor Related
- Acquired (Drug Related)
- Warfarin (Coumadin)
- Unfractionated heparin
- Low molecular weight heparin (i.e. enoxaparin (Lovenox), dalteparin)
- Factor Xa Inhibitors (e.g. rivaroxaban, apixaban, fondaparinux, edoxaban)
- Direct thrombin inhibitors (e.g. dabigatran, argatroban, bivalirudin)
- Illness induced
- Genetic
Diagnosis
- Bleeding time extended past 1-7 min (small incision on finger)
- Mild thrombocytopenia but plts rarely fall below 80k
- PT and aPTT typically remain normal
Management
- Treatment = desmopressin, cryoprecipitate, conjugated estrogen, EPO, dialysis[1]
- Limited evidence for dialysis (peritoneal vs. hemodialysis) in management of acute uremic bleeding
- DDAVP 0.4 mcg/kg IV over 10 min - effects within 1 hr but increased bleeding time returns within 24 hrs[2]
- Cryoprecipitate 10 bags over 30 min - benefit seen within 4-12 hrs in most[3]
- Recombinant EPO 50 - 150 u/kg IV 3x/wk
- Conjugated estrogens at 0.6 mg/kg IV over 30 min QD for 5 days - time to effect ~ 6 hrs, max effect at 1 wk, duration of action 2 wks
See Also
References
- ↑ Hedges SJ et al. Evidence-based treatment recommendations for uremic bleeding. Nature Clinical Practice Nephrology (2007) 3, 138-153.
- ↑ Desmopressin (Rx) - Dosing and Uses. Medscape. http://reference.medscape.com/drug/ddavp-stimate-desmopressin-342819.
- ↑ Cryoprecipitate - Dosing and Uses. Medscape. http://reference.medscape.com/drug/cryo-cryoprecipitate-999498.